Novartis' lung cancer drug gets breakthrough designation

03/19/2013 | PharmaTimes (U.K.)

The FDA granted breakthrough therapy status to Novartis' LDK378 for treatment of patients with anaplastic lymphoma kinase positive metastatic nonsmall-cell lung cancer when crizotinib can't be used. The drug is being tested in two midstage trials, and Novartis plans to initiate several late-stage studies this year. An initial regulatory application is expected early next year.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN